Patients with heart failure who presented an ejection fraction of the left ventricle of 40% or less also had a significantly lower incidence of death from cardiovascular causes and hospitalization after SGLT2 inhibitor therapy in the DAPA-HF trial [10]. The gene discussed is SLC5A2; the disease is heart failure.